



**AALBORG UNIVERSITY**  
DENMARK

**Aalborg Universitet**

## **Editorial**

*Diabetes and bone - from cell to human*

Vestergaard, Peter; Catalano, Antonino; Starup-Linde, Jakob

*Published in:*  
Frontiers in Endocrinology

*DOI (link to publication from Publisher):*  
[10.3389/fendo.2022.1085953](https://doi.org/10.3389/fendo.2022.1085953)

*Creative Commons License*  
CC BY 4.0

*Publication date:*  
2022

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
Vestergaard, P., Catalano, A., & Starup-Linde, J. (2022). Editorial: Diabetes and bone - from cell to human. *Frontiers in Endocrinology*, 13, Article 1085953. <https://doi.org/10.3389/fendo.2022.1085953>

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

### **Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.



## OPEN ACCESS

EDITED AND REVIEWED BY  
Åke Sjöholm,  
Gävle Hospital, Sweden

\*CORRESPONDENCE  
Jakob Starup-Linde  
jakolind@arm.dk

SPECIALTY SECTION  
This article was submitted to  
Clinical Diabetes,  
a section of the journal  
Frontiers in Endocrinology

RECEIVED 31 October 2022  
ACCEPTED 04 November 2022  
PUBLISHED 17 November 2022

CITATION  
Vestergaard P, Catalano A and  
Starup-Linde J (2022) Editorial:  
Diabetes and bone - from  
cell to human.  
*Front. Endocrinol.* 13:1085953.  
doi: 10.3389/fendo.2022.1085953

COPYRIGHT  
© 2022 Vestergaard, Catalano and  
Starup-Linde. This is an open-access  
article distributed under the terms of  
the [Creative Commons Attribution  
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution  
or reproduction in other forums is  
permitted, provided the original  
author(s) and the copyright owner(s)  
are credited and that the original  
publication in this journal is cited, in  
accordance with accepted academic  
practice. No use, distribution or  
reproduction is permitted which does  
not comply with these terms.

# Editorial: Diabetes and bone - from cell to human

Peter Vestergaard<sup>1</sup>, Antonino Catalano<sup>2</sup>  
and Jakob Starup-Linde<sup>3,4\*</sup>

<sup>1</sup>Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark, <sup>2</sup>Unit of Geriatrics, Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy, <sup>3</sup>Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark, <sup>4</sup>Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark

## KEYWORDS

bone, diabetes, fractures, alendronate, antidiabetics medication

## Editorial on the Research Topic

### Diabetes and bone - from cell to human

The interaction between increased glucose levels and fluctuations in these as seen in diabetes is complex. Changes at the cellular level – even within minutes – may have profound effects on the clinical level leading to an increased risk of fractures. The treatments used to counteract hyperglycemia can modify the effects at the cellular, individual and population levels, but they cannot completely undo the negative effects of the hyperglycemic state. Differences in insulin levels and insulin resistance may influence the effects of hyperglycemia between type 1 and type 2 diabetes but may also play a role within type 2 diabetes, where different phenotypes may exist.

This topic spans the levels from observational studies on the cut-off levels for an effect of HbA1c on bone turnover (Joad *et al.*) and prevalence of morphometric vertebral fractures in diabetes and pre-diabetes (Hulten *et al.*) over interventional studies on the effect of diet on bone turnover (Fuglsang-Nielsen *et al.*) to pharmacoepidemiological studies on fracture risk related to various drugs used in diabetes (Al-Mashhadi *et al.*, Al-Mashhadi *et al.*, Zhang *et al.*, Viggers *et al.*), even antiosteoporotic therapy may modify the risk of developing diabetes, showing the potential bone pancreas interplay (Viggers *et al.*), thus demonstrating the necessity to analyse the problem of the bone fragility in diabetes using many different techniques from different fields of science. This also shows that although epidemiological techniques can answer research questions that cannot be answered by preclinical and *in vitro* studies, such as the interaction between diabetes, its treatment, and fracture risk, preclinical studies can elucidate the mechanisms underlying the clinical problem of fractures, which cannot be understood in detail using epidemiology.

On the other hand, interventional studies point out that although understanding and describing a problem is essential, it is also necessary to know whether it is possible to modulate pathophysiological processes and thus potentially prevent fractures in diabetes, modulate possible hypoglycemia, which can lead to falls and fractures, and potentially reverse or prevent complications such as impaired eyesight, which can lead to an increased fracture risk.

We hope that you, too, will feel as inspired and enlightened as we did in editing this Research Topic.

## Author contributions

All authors have drafted and revised the editorial. All authors have approved the final version of the submitted editorial.

## Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.